Abstract
Data from many experiments has shown that serotonin2C (5-HT2C) receptor plays a role in the control of orofacial activity in rodents. Purposeless oral movements can be elicited either by agonists or inverse agonists implying a tight control exerted by the receptor upon oral activity. The effects of agonists has been related to an action of these drugs in the subthalamic nucleus and the striatum, the two input structures for cortical efferents to the basal ganglia, a group of subcortical structures involved in the control of motor behaviors. The oral effects of agonists are dramatically enhanced in case of chronic blockade of central dopaminergic transmission induced by neuroleptics or massive destruction of dopamine neurons. The mechanisms involved in the hypersensitized oral responses to 5-HT2C agonists are not clear and deserve additional studies. Indeed, while the oral behavior triggered by 5-HT2C drugs would barely correspond to the dyskinesia observed in humans, the clinical data have consistently postulated that 5-HT2C receptors could be involved in these aberrant motor manifestations.
Keywords: Serotonin2c receptor, oral activity, neuroleptic, 6-hydroxydopamine lesion, hypersensitized oral responses
Current Neuropharmacology
Title:Serotonin2C Receptors and the Motor Control of Oral Activity
Volume: 11 Issue: 2
Author(s): Melanie Lagiere, Sylvia Navailles, Marion Bosc, Martin Guthrie and Philippe De Deurwaerdere
Affiliation:
Keywords: Serotonin2c receptor, oral activity, neuroleptic, 6-hydroxydopamine lesion, hypersensitized oral responses
Abstract: Data from many experiments has shown that serotonin2C (5-HT2C) receptor plays a role in the control of orofacial activity in rodents. Purposeless oral movements can be elicited either by agonists or inverse agonists implying a tight control exerted by the receptor upon oral activity. The effects of agonists has been related to an action of these drugs in the subthalamic nucleus and the striatum, the two input structures for cortical efferents to the basal ganglia, a group of subcortical structures involved in the control of motor behaviors. The oral effects of agonists are dramatically enhanced in case of chronic blockade of central dopaminergic transmission induced by neuroleptics or massive destruction of dopamine neurons. The mechanisms involved in the hypersensitized oral responses to 5-HT2C agonists are not clear and deserve additional studies. Indeed, while the oral behavior triggered by 5-HT2C drugs would barely correspond to the dyskinesia observed in humans, the clinical data have consistently postulated that 5-HT2C receptors could be involved in these aberrant motor manifestations.
Export Options
About this article
Cite this article as:
Lagiere Melanie, Navailles Sylvia, Bosc Marion, Guthrie Martin and Deurwaerdere De Philippe, Serotonin2C Receptors and the Motor Control of Oral Activity, Current Neuropharmacology 2013; 11 (2) . https://dx.doi.org/10.2174/1570159X11311020003
DOI https://dx.doi.org/10.2174/1570159X11311020003 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Different Aspects of Head and Neck Squamous Cell Carcinoma: Cancer Stem Cells, their Niche and Targeted Therapy
Current Stem Cell Research & Therapy Control of Interleukin-1β Secretion in Inflammation and Immune Response
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Target-Related Affinity Profiling: Teliks Lead Discovery Technology
Current Topics in Medicinal Chemistry Poly(ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Group I Metabotropic Glutamate Receptors: Involvement in Drug-Seeking and Drug-Induced Plasticity
Current Molecular Pharmacology Agrobacterium-Mediated Transient Expression as an Approach to Production of Recombinant Proteins in Plants
Recent Patents on Biotechnology Hydrogen Sulfide-Based Therapies: Focus on H2S Releasing NSAIDs
Inflammation & Allergy - Drug Targets (Discontinued) Beyond the Synapse and Hebb's Rule: Is the Rest of the Neuron More Important for Psychiatric Disorders?
Current Psychiatry Reviews The Use of Thalidomide in Myeloma Therapy as an Effective Anticancer Drug
Current Cancer Drug Targets 2-Aminoethyldiphenyl Borinate: A Multitarget Compound with Potential as a Drug Precursor
Current Molecular Pharmacology Role of Novel Drug Delivery Systems in Coronavirus Disease-2019 (COVID-19): Time to Act Now
Current Drug Delivery Applying Epigenetics to Alzheimer’s Disease via the Latent Early–life Associated Regulation (LEARn) Model
Current Alzheimer Research Antinociceptive Activity of Lectins from Diocleinae Seeds on Acetic Acid-Induced Writhing Test in Mice
Protein & Peptide Letters Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Neuroprotective Effects of Drug-Induced Therapeutic Hypothermia in Central Nervous System Diseases
Current Drug Targets Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) Tinea Capitis: An Updated Review
Recent Patents on Inflammation & Allergy Drug Discovery Antitumor Therapeutic Strategies Based on the Targeting of Epidermal Growth Factor-Induced Survival Pathways
Current Drug Targets Bee Venom: Its Potential Use in Alternative Medicine
Anti-Infective Agents AMPK Function in Aging Process
Current Drug Targets